Novan Inc
F:6LUA
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
This alert will be permanently deleted.
Novan Inc
Accounts Payable
Novan Inc
Accounts Payable Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Accounts Payable | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Novan Inc
F:6LUA
|
Accounts Payable
$13.7m
|
CAGR 3-Years
105%
|
CAGR 5-Years
95%
|
CAGR 10-Years
N/A
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Accounts Payable
$9.6B
|
CAGR 3-Years
-6%
|
CAGR 5-Years
0%
|
CAGR 10-Years
4%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Accounts Payable
$4.3B
|
CAGR 3-Years
18%
|
CAGR 5-Years
12%
|
CAGR 10-Years
13%
|
|
|
Pfizer Inc
NYSE:PFE
|
Accounts Payable
$5B
|
CAGR 3-Years
-7%
|
CAGR 5-Years
4%
|
CAGR 10-Years
4%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Accounts Payable
$4.1B
|
CAGR 3-Years
7%
|
CAGR 5-Years
2%
|
CAGR 10-Years
7%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Accounts Payable
$4.3B
|
CAGR 3-Years
36%
|
CAGR 5-Years
24%
|
CAGR 10-Years
14%
|
|
Novan Inc
Glance View
Novan, Inc. is a biotechnology company, which engages in leveraging nitric oxide’s natural antiviral and immunomodulatory mechanisms of action to treat dermatological and oncovirus-mediated diseases. The company is headquartered in Durham, North Carolina and currently employs 29 full-time employees. The company went IPO on 2016-09-21. The firm is engaged in researching, developing and marketing products for skin diseases. The firm is focused on dermatology and anti-infective therapies. Its technology platform leverages nitric oxide’s naturally occurring anti-viral, anti-bacterial, anti-fungal, and immunomodulatory mechanisms of action to treat a range of diseases. The firm has clinical-stage dermatology and anti-infective drug candidates with multi-factorial (SB204), anti-viral (SB206), anti-fungal (SB208), and anti-inflammatory (SB414) mechanisms of action. The Company’s lead product candidate is SB206, which is a topical gel with anti-viral properties for the treatment of viral skin infections, with focus on molluscum contagiosum. The firm is exploring the potential of its NITRICIL technology as a potential treatment option for COVID-19, targeting the reduction of viral shedding and transmission.
See Also
What is Novan Inc's Accounts Payable?
Accounts Payable
13.7m
USD
Based on the financial report for Dec 31, 2022, Novan Inc's Accounts Payable amounts to 13.7m USD.
What is Novan Inc's Accounts Payable growth rate?
Accounts Payable CAGR 5Y
95%
Over the last year, the Accounts Payable growth was 531%. The average annual Accounts Payable growth rates for Novan Inc have been 105% over the past three years , 95% over the past five years .
